Logo

PRFX

PainReform Ltd.

PRFX

PainReform Ltd. • NASDAQ
$0.96 ▲ 4.32% (+0.04)
Market Cap $1.94 M
52w High $16.63
52w Low $0.80
Dividend Yield 0%
P/E 0.03
Volume 39.70K
Outstanding Shares 2.01M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q2-2025 $0 $1.184M $-1.158M 0% $-0.55 $-1.093M
Q1-2025 $0 $1.184M ▲ $-1.158M ▼ 0% $-0.55 ▲ $-1.093M ▼
Q4-2024 $0 $881.5K $-885K 0% $-0.6 $-877.5K
Q3-2024 $0 $881.5K ▼ $-885K ▲ 0% $-0.6 ▲ $-877.5K ▲
Q2-2024 $0 $7.345M $-7.312M 0% $-50.599 $-7.341M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q2-2025 $3.479M $11.162M $2.719M $8.443M
Q1-2025 $3.479M ▼ $11.162M ▲ $2.719M ▲ $8.443M ▲
Q4-2024 $4.261M $4.525M $2.701M $1.824M
Q3-2024 $4.261M ▲ $4.525M ▲ $2.701M ▼ $1.824M ▲
Q2-2024 $2.783M $3.107M $5.148M $-2.041M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q2-2025 $-1.158M $-991K $-25K $623.5K $0 $-991K
Q1-2025 $-1.158M ▼ $-991K ▲ $-25K ▼ $623.5K ▼ $0 $-991K ▲
Q4-2024 $-885K $-1.988M $-500 $2.727M $0 ▲ $-1.989M
Q3-2024 $-885K ▲ $-1.988M ▲ $-500 ▲ $2.727M ▼ $-2.793M ▼ $-1.989M ▲
Q2-2024 $-7.312M $-4.949M $-5K $3.41M $-1.541M $-4.954M

Five-Year Company Overview

Income Statement

Income Statement PainReform is still a pre-commercial company. It has not generated meaningful product revenue over the last several years and relies on funding rather than sales. Operating expenses related to R&D, administration, and public-company costs drive recurring losses. Although the absolute loss levels are small in corporate terms, they are large relative to the company’s tiny scale. Overall, the income statement reflects an early-stage business still in development mode, not yet in a revenue-generating phase.

Balance Sheet

Balance Sheet The balance sheet is very thin. Assets and cash are modest, equity is limited, and there is no meaningful debt reported. The absence of debt reduces financial leverage risk, but the small cash base and tiny asset base leave little cushion for setbacks. The company’s financial strength depends heavily on its ability to raise additional capital in the future, and the series of reverse stock splits hints at past pressure on the share price and equity base.

Cash Flow

Cash Flow Cash flows show a consistent pattern of money going out to fund operations and development, with no offsetting inflows from commercial activity. Operating cash burn has been steady over time, and there is essentially no spending on heavy equipment or facilities, which fits a research- and software-focused model. This means the main ongoing need is to finance staff, trials, and technology development. The company looks dependent on external financing to sustain its projects until either its drug candidates or its solar platform generate recurring revenue.

Competitive Edge

Competitive Edge Competitively, PainReform is trying to play in two very demanding arenas at once: specialty pharmaceuticals and AI-powered clean energy software. In pain management, it faces large and well-funded drug companies, and its lead asset has already experienced a late-stage clinical setback, which weakens its near-term positioning. In solar analytics, the DeepSolar platform has some early validation and a modern AI angle, but it operates in a crowded field with many analytics and software providers. Overall, the company’s scale is small relative to competitors in both segments, so execution, partnerships, and differentiation will be critical to gaining traction.

Innovation and R&D

Innovation and R&D Innovation is the clear focus of PainReform. On the pharma side, it is advancing proprietary extended-release drug delivery for surgical pain, aiming to reduce opioid use and extend relief after operations, including new combinations that add anti-inflammatory effects. It is also experimenting in ophthalmology via its stake in a “dropless” post-surgery eye treatment. On the clean energy side, DeepSolar’s AI-driven platform and its work on more accurate solar forecasting, supported by a major chip maker’s AI program, stand out as technologically ambitious. The R&D pipeline is conceptually attractive but carries high regulatory, technical, and commercialization risk in both domains.

Summary

PainReform is a very early-stage, high-uncertainty story with two distinct bets: a non-opioid pain platform in pharmaceuticals and an AI analytics platform in solar energy. Financially, it has no meaningful revenue, runs ongoing losses, and operates with a very small balance sheet, implying continued reliance on capital markets. The clinical setback in its lead drug adds uncertainty to the pharma path, while DeepSolar offers a more software-like growth narrative but is still in its early commercialization phase. The combination of limited financial resources, dual-sector focus, and ambitious R&D creates both upside optionality and considerable execution and funding risk. Overall, this is a development-stage company whose future will largely depend on clinical milestones, technology adoption, and its ability to secure sufficient capital along the way.

NEWS

November 12, 2025 · 9:00 AM UTC

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

Read more

November 5, 2025 · 8:30 AM UTC

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

Read more

October 1, 2025 · 9:27 AM UTC

PainReform Provides Business Update for the Six Months Ended June 30, 2025

Read more